[Skip to Content]
[Skip to Content Landing]
Views 1,417
Citations 0
Clinical Trials Update
February 27, 2018

Stem Cell Transplantation Improves Scleroderma Outcomes

JAMA. 2018;319(8):761. doi:10.1001/jama.2018.1204

Myeloablative autologous hematopoietic stem cell transplantation resulted in significantly better long-term clinical outcomes—although greater toxicity–in patients with scleroderma than did cyclophosphamide, found a trial published in the New England Journal of Medicine.

The 75 participants with severe scleroderma were randomly assigned to undergo myeloablative autologous stem cell transplantation or to receive cyclophosphamide.